Published in AIDS Weekly, August 30th, 1999
Proleukin, a recombinant form of Interleukin-2, also known as T-cell growth factor, is being administered in combination with anti-HIV therapy in people with HIV infection. This pivotal study's primary objective is to determine if intermittent cycles of Proleukin delay the progression of HIV disease compared to what is observed with anti-HIV therapy alone...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.